Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459738) titled 'A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer' on March 5.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shanghai Henlius Biotech

Condition: Hormone Receptor Positive HER-2 Negative Breast Cancer

Intervention: Drug: HLX43

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: April 1, 2026

Target Sample Size: 60

To know more, visit h...